Evidence map›Paper›PMID 36673070›Full record

ArticleDiagnostics (Basel, Switzerland)2023

Automated Pneumonia Based Lung Diseases Classification with Robust Technique Based on a Customized Deep Learning Approach.

Yaman Akbulut

Open access · goldAbstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Yaman AkbulutDepartment of Software Engineering, Faculty of Technology, Firat University, Elazig 23200, Turkey.ORCID 0000-0002-4760-4843
Fırat University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many people have been affected by infectious lung diseases (ILD). With the outbreak of the COVID-19 disease in the last few years, many people have waited for weeks to recover in the intensive care wards of hospitals. Therefore, early diagnosis of ILD is of great importance to reduce the occupancy rates of health institutions and the treatment time of patients. Many artificial intelligence-based studies have been carried out in detecting and classifying diseases from medical images using imaging applications. The most important goal of these studies was to increase classification performance and model reliability. In this approach, a powerful algorithm based on a new customized deep learning model (ACL model), which trained synchronously with the attention and LSTM model with CNN models, was proposed to classify healthy, COVID-19 and Pneumonia. The important stains and traces in the chest X-ray (CX-R) image were emphasized with the marker-controlled watershed (MCW) segmentation algorithm. The ACL model was trained for different training-test ratios (90-10%, 80-20%, and 70-30%). For 90-10%, 80-20%, and 70-30% training-test ratios, accuracy scores were 100%, 96%, and 96%, respectively. The best performance results were obtained compared to the existing methods. In addition, the contribution of the strategies utilized in the proposed model to classification performance was analyzed in detail. Deep learning-based applications can be used as a useful decision support tool for physicians in the early diagnosis of ILD diseases. However, for the reliability of these applications, it is necessary to undertake verification with many datasets.

Indexed as

customized deep learningILDMCW segmentation

Identifiers

PMID36673070
PMCPMC9858391
OpenAlexW4315567905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.